Yuanda Pharmaceutical liver cancer treatment products are admitted to the hospital for layout of radioactive nuclear drugs all industrial chain

Today (June 19), Yuanda Pharmaceutical (HK00512, HK $ 4.38, a market value of HK $ 15.547 billion) is used to treat global innovative products for the treatment of malignant tumors in the liver. The National Listing Society is held online. This means that after being approved by the State Drug Administration for more than 4 months, the 钇 [90Y] microsphere injection has been officially put into the hospital for use.

From the perspective of the mechanism of action, 0 [90Y] Microfin injection is a targeted internal radiation nuclein product for liver malignant tumors. By interventional technology, 钇 [90Y] is injected into liver tumor blood vessels and released high -energy β radiation to kill the tumor Cells are regarded as "nuclear weapons" level innovation treatment methods provided to patients with liver cancer patients.

According to the information provided by Yuanda Pharmaceutical, in 2002, 钇 [90Y] micro -ball injection was approved for listing in the United States and the European Union for the first time. After 20 years, it is still the only world for colorectal cancer. product. Dong Jiahong, an academician of the Chinese Academy of Engineering and the dean of Tsinghua Chang Gung Hospital, Tsinghua University, believes that the doctor's precise operation 钇 [90Y] microsphere injection can achieve effective control of patients with middle and advanced liver cancer. Opportunities for healing surgery such as resection or liver transplantation have become the "new types of weapons" in my country to overcome liver cancer.

From the acquisition of Sirtex from the 2018 Yuanda Pharmaceutical Union with CDH GENETECH, the introduction of Sir-SPHERES 钇 [90Y] microsphere injection, and now the product is admitted to the admission, it is enough to see the importance of Yuanda Medicine for the radioactive drug diagnosis and treatment platform.

According to the annual report of Yuanda Pharmaceutical's 2021, the group conducts a key global layout of three areas of globalization around "tumor intervention", "radioactuclide-drug conjugate (RDC)" and "immunotherapy". Among them, the radioactive nuclear drug diagnosis and treatment platform is a high -end technology platform that the company focuses on the anti -tumor field, and the 钇 [90Y] microsphere injection is a heavy global innovation product for radioactive ribin antitumor drugs.

The annual report shows that in the next 1 to 2 years, Yuanda Pharmaceutical will continue to strengthen the research and development and investment in the field, establish at least 1 Grade A qualification production platform, complete the pipeline layout of more than 25 radioactive nuclear diagnosis and treatment products, and form a 钇 [90Y] Micro ball injection is a radioactive drug product group with core.

Tang Weikun, the president of Yuanda Pharmaceutical, believes that with the gradual entering the domestic three hospitals, 钇 [90Y] micro -ball injection will provide a large number of patients with malignant tumors in China with a new and effective treatment method, creating potential surgical resection opportunities to make up for it to make up for The gaps of local treatment of colorectal cancer, and marked the in the field of liver malignant tumors in China ushered in a new international and precise intervention treatment plan.

It is reported that 10 innovative products have been reserved for the radioactive drug diagnosis and treatment platform of Yuanda Pharmaceutical, covering 6 types of nucleo, including 68GA, 177LU, 131i, 90Y, 89ZR, and 99MTC. Adaptive disease covers liver cancer, prostate cancer, colorectal cancer, transparent cells, transparent cells Thirteen cancer species including renal cell carcinoma, cerebral gel tumor, gastrointestinal pancreatic neuromuscular endocrine tumor, and malignant tumor bone metastasis. The product types include two types of nuclein drugs, which can provide patients with multiple cancer species and more. Anti -tumor schemes that are integrated by means and integrated diagnosis and treatment.

Daily Economic News

- END -